Who
Gary S. Stetz II
Director
Company insider
Files Form 4 as: Director, Hepion Pharmaceuticals.
In numbers
- Trades disclosed
- 6
- Buys
- 1
- Sells
- 0
- Bought
- $50K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 3 Aug 2026
- Last trade
- 19 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 21 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —299,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —299,000 at $0.00 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K500,000 at $0.05 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —500,000 at $0.00 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —500,000 at $0.00 | filing |
| 3 Aug 2026filed 12 Aug 2026 | Hepion PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $25K500,000 at $0.05 | filing |
News
No headline names them, or the companies they trade most, lately.